BenoÃ®t Brethon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2712345/publications.pdf

Version: 2024-02-01

29	518	933447	677142
papers	citations	10	22
		h-index	g-index

31	31	31	913
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood, 2018, 131, 289-300.	1.4	97
2	COVIDâ€19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms?. Pediatric Blood and Cancer, 2020, 67, e28392.	1.5	74
3	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer Journal, 2020, 10, 77.	6.2	65
4	Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica, 2019, 104, e244-e247.	3.5	52
5	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood, 2021, 137, 1582-1590.	1.4	48
6	Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Journal of Clinical Oncology, 2021, 39, 652-662.	1.6	41
7	Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report from the French Society of Pediatric Oncology. Cancers, 2020, 12, 3398.	3.7	26
8	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Advances, 2022, 6, 1004-1014.	5.2	22
9	Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia. Frontiers in Oncology, 2021, 11, 637951.	2.8	17
10	Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22 â€positive Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 190, e53-e56.	2.5	15
11	A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee). Pediatric Blood and Cancer, 2016, 63, 270-275.	1.5	10
12	Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study. Journal of Pediatrics, 2021, 236, 204-210.	1.8	10
13	Impact of COVIDâ€19 on cancer care: A survey from the French Society of Pediatric Oncology (SFCE). Pediatric Blood and Cancer, 2021, 68, e28554.	1.5	8
14	Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients. Pharmaceuticals, 2022, 15, 375.	3.8	7
15	Tolerance to arsenic trioxide combined with allâ€transâ€retinoic acid in children with acute promyelocytic leukaemia in France. British Journal of Haematology, 2020, 188, 170-173.	2.5	6
16	End-of-life care in children and adolescents with cancer: perspectives from a French pediatric oncology care network. Tumori, 2021, , 030089162110133.	1.1	5
17	High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study. Blood, 2018, 132, 1375-1375.	1.4	3
18	Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. Blood, 2018, 132, 5203-5203.	1.4	2

#	Article	IF	Citations
19	Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO). Blood, 2020, 136, 24-25.	1.4	2
20	Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines. Blood, 2016, 128, 1083-1083.	1.4	2
21	Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study. Blood, 2019, 134, 5130-5130.	1.4	1
22	Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium. Blood, 2014, 124, 989-989.	1.4	1
23	Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers. Blood, 2016, 128, 5190-5190.	1.4	1
24	Safety of Clofarabine with Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (Vandevol study of the French SFCE Acute Leukemia Committee).. Blood, 2012, 120, 2570-2570.	1.4	0
25	Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol. Blood, 2012, 120, 135-135.	1.4	0
26	Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3723-3723.	1.4	0
27	Immunophenotypic Profiling of Childhood B-Cell Precursor Acute Lymphoblastic Helps Identifying Genetic Subtypes, Including Recently Identified Ones. Blood, 2016, 128, 2910-2910.	1.4	0
28	Late Effects in Survivors of Infantile Acute Leukemia Are Less Severe Than Expected: A Study of the L.E.a Program. Blood, 2016, 128, 3571-3571.	1.4	0
29	Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Blood, 2021, 138, 2383-2383.	1.4	0